Group 1: Pharmaceutical and Biotechnology Industry - The pharmaceutical and biotechnology sector saw an overall increase of 0.14% last week, outperforming the CSI 300 index by 1.47 percentage points, with a current PE valuation of 29.43 times, which is at a historical mid-low level, representing a 120% premium over the CSI 300 [6][7] - Notable individual stock performances included Guangshengtang, which surged by 29.83%, followed by Haixiang Pharmaceutical at 18.64%, and Meidisi at 18.04% [6] - A significant collaboration was announced between Saint Gene and Gene Tech, involving a global R&D cooperation and licensing agreement for an RNAi therapy, with an upfront payment of $200 million and potential milestone payments totaling $1.5 billion [7][8] - The investment recommendation focuses on three main lines: biotech firms with core delivery technology and international collaboration potential, industry leaders in chronic disease areas with advanced pipelines, and key companies in the small nucleic acid supply chain benefiting from global commercialization [8] Group 2: Machinery and Equipment Industry - In January 2026, excavator sales reached 18,708 units, a year-on-year increase of 49.5%, with domestic sales up 61.4% and exports up 40.5% [11][12] - Loader sales also saw significant growth, with a total of 11,759 units sold in January, reflecting a 48.5% increase year-on-year, driven by major domestic projects [13] - The demand for excavators is expected to continue recovering due to upcoming large-scale projects in various sectors, including mining and water conservancy [12][14] - Companies like LiuGong are projected to see steady profit growth, with a forecasted net profit of 1.526 to 1.659 billion yuan for 2025, marking a 15-25% increase year-on-year [13] Group 3: Electronics Industry - The electronics sector is experiencing a recovery, with significant capital expenditure increases from major CSP manufacturers, expected to reach $670 billion in 2026, a 60% year-on-year increase [16][17] - The global semiconductor industry is projected to achieve record sales of $791.7 billion in 2025, with a 25.6% year-on-year growth, driven by demand from AI and IoT technologies [18] - Price increases are spreading from memory chips to power, analog, and MCU chips, indicating a comprehensive price surge in the semiconductor market [18] - Investment recommendations include focusing on companies benefiting from strong domestic and international demand in the AIOT sector, as well as those involved in semiconductor equipment and materials [21]

A股这7大板块，勾勒出中 国经济全貌 出品 | 妙投APP 作者 | 妙投团队 编辑 | 丁萍 头图 | AI制图 幸福的人大致相同，不幸的人各有各的不幸。 银河证券研报显示，截至1月31日，2956家A股上市公司已披露2025年年报业绩预告，披露率为54%。其中 电机、地面兵装、个护用品、风电设备预喜率 （包括扭亏、续盈、略增、预增等情形） 超过70%，汽车行 业超过50%，受益于AI算力需求的电子和通信行业，预喜率分别达到45%和37%。这些大体上属于科技、高 端制造、新消费等领域。 而传统行业，大多较为一般。 煤炭、房地产、轻工制造、建筑装饰、食品饮料、社会服务、石油石化等行业预喜率较低，均低于25%； 焦炭、体育、林业、农业综合、厨卫电器、油气开采、白酒行业预喜率更是均为0%；传统行业中预喜率较 高的，主要是非银金融、有色金属、钢铁、公用事业等少数行业。 展望2026年，有些业绩不错的行业，有望继续保持成长。而有些2025年经营惨淡的行业，也有边际复苏的 机会，或者有复苏的预期。 这句话放到宏观经济各个层面中来看，也是如此。有的行业经历着良好的增长，有的行业在期待着复苏的 曙光。 2025年到现在，无 ...

Group 1 - The core point of the article is that Yifeng Pharmacy announced that its stock price has been below 85% of the current conversion price of 31.84 yuan for 15 trading days, triggering the adjustment clause for "Yifeng Convertible Bonds" [2] - The board of directors decided not to adjust the conversion price during the period from February 6 to May 5, 2026, and the next recalculation period is expected to start on May 6, 2026 [2]

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2026-005 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于不向下修正"益丰转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 自 2026 年 1 月 16 日至 2026 年 2 月 5 日，公司股票的收盘价已在任意连 续三十个交易日中有十五个交易日低于当期转股价格的 85%，已触发"益丰转债" 转股价格修正条款。 公司于 2026 年 2 月 5 日召开第五届董事会第二十五次会议，审议通过了 《关于不向下修正"益丰转债"转股价格的议案》。公司决定本次不向下修正"益 丰转债"的转股价格，并且在未来 3 个月内（即 2026 年 2 月 6 日至 2026 年 5 月 5 日），公司股价若再次触发此条款，亦不向下修正"益丰转债"的转股价格。 下一触发转股价格修正条款的期间从 2026 年 5 月 6 日起重新计算，若公司股价 再 ...

Group 1 - The core viewpoint of the article indicates that the internet healthcare sector experienced a slight increase of 0.0% on February 4, with Yifeng Pharmacy leading the gains [1] - The Shanghai Composite Index closed at 4102.2, reflecting an increase of 0.85%, while the Shenzhen Component Index closed at 14156.27, up by 0.21% [1] - The net capital flow in the internet healthcare sector showed a net outflow of 1.928 billion yuan from major funds, while retail investors contributed a net inflow of 1.255 billion yuan [1] Group 2 - The article provides a detailed breakdown of the capital flow within the internet healthcare sector, highlighting that speculative funds had a net inflow of 0.673 billion yuan [1] - The article includes a table summarizing the individual stock performance and capital flow within the internet healthcare sector, although specific stock details are not provided in the text [1]

Market Overview - The pharmaceutical commercial sector increased by 1.34% on February 4, with Yifeng Pharmacy leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Stock Performance - Yifeng Pharmacy (603939) closed at 24.76, up 4.96% with a trading volume of 180,700 shares [1] - Dazhenlin (603233) rose by 3.27% to 19.88, with a trading volume of 82,100 shares and a transaction value of 161 million [1] - Fuzhong (002462) increased by 2.80% to 16.86, with a trading volume of 337,400 shares [1] - Login Medical (002788) saw a 2.60% rise to 16.60, with a trading volume of 367,300 shares [1] - Other notable stocks include Nanjing Pharmaceutical (600713) up 2.03% and Jianzhijia (605266) up 1.95% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 18.375 million from institutional investors, while retail investors saw a net outflow of 34.4782 million [2] - Conversely, speculative funds recorded a net inflow of 52.8532 million [2] Individual Stock Capital Flow - Luyan Pharmaceutical (002788) had a net inflow of 42.3085 million from institutional investors, while retail investors faced a net outflow of 72.3406 million [3] - Yifeng Pharmacy (603939) saw a net inflow of 20.1487 million from institutional investors and a net outflow of 57.1720 million from retail investors [3] - Huaren Health (301408) had a net inflow of 12.3779 million from institutional investors, with a net outflow of 15.7068 million from retail investors [3]

Investment Rating - The report maintains an "Overweight" rating for the medical consumables industry and offline pharmacy sector [5][6]. Core Insights - The medical consumables market is expected to recover, with positive performance anticipated for innovative high-value consumables due to factors such as aging population, increased demand for medical services, and improved domestic production rates [3]. - The offline pharmacy industry is transitioning from a period of rapid expansion to a focus on operational efficiency and service value, driven by policy guidance that encourages industry consolidation [4]. Summary by Sections Medical Consumables Industry - The market is experiencing a recovery in confidence, with expectations for improved performance in high-value consumables [3]. - Investment focus areas include: 1. Performance reversal in segments like orthopedic consumables, exemplified by companies such as Weigao Orthopedics [5]. 2. Increased market penetration of low-penetration consumables, particularly in high-end innovative fields [5]. 3. Expansion into overseas markets, with orthopedic and interventional consumables leading the way [5]. Offline Pharmacy Industry - The industry is set for accelerated consolidation, moving towards high-quality development characterized by operational efficiency and resource optimization among leading brands [4]. - Key companies to watch include those with advantages in compliance, supply chain, and digital management, such as Yifeng Pharmacy [6]. Market Performance - The medical consumables sector reported a 17.02% increase in the past year, indicating a strong recovery compared to the broader market [17]. - The report highlights the performance of leading companies in the medical consumables sector, with significant growth observed in companies like Hualan Biological Engineering and ZhenDe Medical [20][25].

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2026-004 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于使用闲置募集资金进行现金管理的公告 特别风险提示 公司将对投资产品进行严格评估，尽管公司选择本金保障类理财产品，但金 融市场受宏观经济的影响较大，不排除该项投资受到市场波动的影响，面临收益 波动风险、流动性风险、信用风险、操作风险、信息技术系统风险、政策法律风 险、不可抗力及意外事件风险、信息传递等风险。 投资种类：结构性存款 投资金额：人民币 11,200 万元 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已履行的审议程序：公司于 2025 年 4 月 15 日召开的第五届董事会第 十五次会议审议通过了《关于使用部分闲置募集资金委托理财的议案》，同 意在确保不变相改变募集资金用途与不影响募集资金投资项目正常运行的情 况下，使用最高额度不超过 30,000 万元募集资金进行委托理财，用于购买 ...

证券研究报告 | 行业简评报告 2026 年 02 月 03 日 布局消费反转！ 大消费组二月消费金股 研究部/消费品 % 1m 6m 12m 绝对表现 4.3 4.6 25.0 相对表现 3.1 -8.7 1.7 资料来源：公司数据、招商证券 -10 0 10 20 30 Feb/25 May/25 Sep/25 Jan/26 (%) 消费品 沪深300 相关报告 1、《招商证券 1 月港股消费观察： 外卖反垄断如何影响港股消费股前 景？》2026-01-27 2、《大消费组一月消费金股—双节 消费亮点前瞻》2026-01-06 ❑ 轻纺 杨蕊菁：看好家居板块修复以及倍加洁益生菌业务发展 风险提示：消费下行风险，消费复苏疲软风险、宏观经济变动风险等。 推荐（维持） 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 1216 | 23.5 | | 总市值（十亿元） | 17628.3 | 15.6 | | 流通市值（十亿元） | 16321.4 | 15.9 | 行业指数 3、《招商证券 12 月港股消费观察— 1-2 月流动性改善后港股消费买什 么？》2025 ...

Core Insights - The 2025 Hurun China Brand List was released, marking the 20th edition of the list, which now includes non-Chinese brands that serve Chinese consumers for the first time [1][6] - Apple tops the list with a brand value of 1.11 trillion RMB, followed by Kweichow Moutai at 795 billion RMB, and WeChat at 325 billion RMB, which saw the highest growth among Chinese brands [4][5] Brand Rankings - The top five brands are: 1. Apple - 1,110 billion RMB (USA, Consumer Electronics) [4] 2. Kweichow Moutai - 795 billion RMB (China) [4] 3. WeChat - 325 billion RMB (China, +38%) [4] 4. Douyin - 280 billion RMB (China, +14%) [4] 5. Tesla - 270 billion RMB (USA, New Entry) [4] Industry Insights - The consumer electronics sector has surpassed the liquor industry to become the highest-valued industry on the list, while liquor remains the highest-valued industry for domestic brands [5] - A total of 386 brands from China made the list, leading the rankings, followed by 46 from the USA and 19 from France [5] Regional Highlights - Hunan province has six brands on the list, including Furong Wang at 18th, Aier Eye Hospital at 131st, and Mango TV at 214th [5] - Shanghai is the city with the most brands on the list, contributing 136 brands, followed by Beijing with 104 [5] New Entries - 212 new brands were added to the list, primarily from the food and beverage and daily chemical industries, with notable entries like Red Bull and Coca-Cola [5][6] - The automotive sector also saw significant new entries, including Tesla and Toyota [5] Brand Value Growth - The total brand value of the listed brands reached nearly 8.8 trillion RMB, an increase of 47% from the previous year [6] - The thresholds for the top 300, 200, and 100 brands have increased, indicating a rise in brand value requirements [6]